Daiwa Securities Group Inc. Aeglea Bio Therapeutics, Inc. Transaction History

Daiwa Securities Group Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 04, 2021	SELL	$7.02 - $9.83 $1,095 - $1,533	-156 Reduced 61.42%	98 $1,000
Q3 2020 Nov 02, 2020	BUY	$6.51 - $9.33 $637 - $914	98 Added 62.82%	254 $2,000
Q1 2019 Apr 26, 2019	BUY	$7.6 - $9.4 $1,185 - $1,466	156 New	156 $1,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.